Photobiomodulation therapy in management of cancer therapy-induced side effects: WALT position paper 2022
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Disclaimer: This article is based on recommendations from the 12 th WALT Congress, Nice, October 3-6, 2018, and a follow-up review of the existing data and the clinical observations of an international multidisciplinary panel of clinicians and researchers with expertise in the area of supportive care in cancer and/or PBM clinical application and dosimetry. This article is informational in nature. As with all clinical materials, this paper should be used with a clear understanding that continued research and practice could result in new insights and recommendations. The review reflects the collective opinion and, as such, does not necessarily represent the opinion of any individual author. In no event shall the authors be liable for any decision made or action taken in reliance on the proposed protocols. Objective: This position paper reviews the potential prophylactic and therapeutic effects of photobiomodulation (PBM) on side effects of cancer therapy, including chemotherapy (CT), radiation therapy (RT), and hematopoietic stem cell transplantation (HSCT). Background: There is a considerable body of evidence supporting the efficacy of PBM for preventing oral mucositis (OM) in patients undergoing RT for head and neck cancer (HNC), CT, or HSCT. This could enhance patients’ quality of life, adherence to the prescribed cancer therapy, and treatment outcomes while reducing the cost of cancer care. Methods: A literature review on PBM effectiveness and dosimetry considerations for managing certain complications of cancer therapy were conducted. A systematic review was conducted when numerous randomized controlled trials were available. Results were presented and discussed at an international consensus meeting at the World Association of photobiomoduLation Therapy (WALT) meeting in 2018 that included world expert oncologists, radiation oncologists, oral oncologists, and oral medicine professionals, physicists, engineers, and oncology researchers. The potential mechanism of action of PBM and evidence of PBM efficacy through reported outcomes for individual indications were assessed. Results: There is a large body of evidence demonstrating the efficacy of PBM for preventing OM in certain cancer patient populations, as recently outlined by the Multinational Association for Supportive Care in Cancer/International Society of Oral Oncology (MASCC/ISOO). Building on these, the WALT group outlines evidence and prescribed PBM treatment parameters for prophylactic and therapeutic use in supportive care for radiodermatitis, dysphagia, xerostomia, dysgeusia, trismus, mucosal and bone necrosis, lymphedema, hand-foot syndrome, alopecia, oral and dermatologic chronic graft-versus-host disease, voice/speech alterations, peripheral neuropathy, and late fibrosis amongst cancer survivors. Conclusions: There is robust evidence for using PBM to prevent and treat a broad range of complications in cancer care. Specific clinical practice guidelines or evidence-based expert consensus recommendations are provided. These recommendations are aimed at improving the clinical utilization of PBM therapy in supportive cancer care and promoting research in this field. It is anticipated these guidelines will be revised periodically.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Seretny, M., Currie, G. L., Sena, E. S., Ramnarine, S., Grant, R., MacLeod, M. R., Colvin, L. A., & Fallon, M. (2014) · Pain · doi:10.1016/j.pain.2014.09.020 · Cited by 1,555
MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy
Lalla, R. V., Bowen, J., Barasch, A., Elting, L., Epstein, J., Keefe, D. M., McGuire, D. B., Migliorati, C., Nicolatou‐Galitis, O., Peterson, D. E., et al. (2014) · Cancer · doi:10.1002/cncr.28592 · Cited by 1,110
Self-citationChemotherapy-induced peripheral neuropathy: a current review
Staff, N. P., Grisold, A., Grisold, W., & Windebank, A. J. (2017) · Annals of Neurology · doi:10.1002/ana.24951 · Cited by 908
Radiation-induced fibrosis: mechanisms and implications for therapy
Straub, J. M., New, J., Hamilton, C. D., Lominska, C., Shnayder, Y., & Thomas, S. M. (2015) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-015-1974-6 · Cited by 677
Overview of neuropathy associated with taxanes for the treatment of metastatic breast cancer
Rivera, E., & Cianfrocca, M. (2015) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-014-2607-5 · Cited by 159
Metadata
- Authors
- Robijns, J., Nair, R. G., Lodewijckx, J., Arany, P., Barasch, A., Bjordal, J. M., Bossi, P., Chilles, A., Corby, P. M., Epstein, J. B., Elad, S., Fekrazad, R., Fregnani, E. R., Genot, M.-T., Ibarra, A. M. C., Hamblin, M. R., Heiskanen, V., Hu, K., Klastersky, J., Lalla, R., Latifian, S., Maiya, A., Mebis, J., Migliorati, C. A., Milstein, D. M. J., Murphy, B., Raber-Durlacher, J. E., Roseboom, H. J., Sonis, S., Treister, N., Zadik, Y., Bensadoun, R.-J., & “Cancer Supportive Care” WALT Working Group
- Venue
- Frontiers in Oncology
- Publisher
- Frontiers Media SA
- Published
- 2022-08-30
- Volume
- 12
- Pages
- 927685-927685
- ISSN
- 2234-943X (ISSN-L)
- OpenAlex
- W4293589635
- Cited by
- 175
- References
- 5
- FWCI
- 17.63
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Photobiomodulation therapy in management of cancer therapy-induced side effects: WALT position paper 2022. https://app.cochat.ai/papers/10.3389/fonc.2022.927685
- The paper
- Robijns, J., Nair, R. G., Lodewijckx, J., Arany, P., Barasch, A., Bjordal, J. M., Bossi, P., Chilles, A., Corby, P. M., Epstein, J. B., Elad, S., Fekrazad, R., Fregnani, E. R., Genot, M.-T., Ibarra, A. M. C., Hamblin, M. R., Heiskanen, V., Hu, K., Klastersky, J., . . . “Cancer Supportive Care” WALT Working Group. (2022). Photobiomodulation therapy in management of cancer therapy-induced side effects: WALT position paper 2022. Frontiers in Oncology. https://doi.org/10.3389/fonc.2022.927685
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.